All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Project Article: J. Med. Chem | Phenotypic Screening and RFD‑Based Synergistic Strategies: In‑Depth Analysis of Multi‑Target Drug Design and Its Application in Alzheimer’s Disease Therapy

　　Alzheimer’s disease (AD) is a complex neurodegenerative disorder involving multiple pathogenic mechanisms, such as β‑amyloid accumulation and abnormal tau phosphorylation. Conventional drugs typically target a single molecular pathway, resulting in limited efficacy, whereas multi‑target drugs (MTDLs) can simultaneously modulate several targets; however, designing such compounds is extremely challenging and often relies on serendipitous discoveries.

　　Recently, a team from China Pharmaceutical University published in the Journal of Medicinal Chemistry an article titled “Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies,” further detailing an innovative polypharmacological drug‑design approach. By combining phenotypic screening with the restricted fragment docking (RFD) method, this strategy offers new insights and methodologies for Alzheimer’s disease drug discovery.

　　

 

　　Research findings

　　| Construction of disease‑related microglial phenotypes and identification of cooperative targets via mechanism‑based siRNA screening

　　

 

　　The authors first established a TLR4‑induced necroptotic phenotype in microglia and, through mechanism‑based siRNA screening, identified MAP4K4 and ALK as potential targets that act in concert with RIPK1. Combined treatment with selective inhibitors of RIPK1, MAP4K4, and ALK revealed that multiple low‑dose regimens can synergistically enhance neuroprotective effects in microglia.

　　|In the Silico-MTDL design, constrained fragment docking is used to simultaneously target RIPK1/MAP4K4/ALK.

　　

 

　　Customized high-throughput virtual screening was performed based on the structural architecture of RIPK1, yielding promising fragment compounds that were subsequently optimized to afford LP‑5b. Employing the RFD approach, the RFD binding site was identified via induced-fit docking, thereby validating the reliability of this method. Structure–activity relationship (SAR) studies conducted on the template MTDL LP‑1d ultimately pinpointed LP‑10d as the optimal ligand, exhibiting nanomolar potency against necroptosis in microglial cells.

　　

 

　　

 

　　| Validation of LP-10d as a brain-penetrant compound targeting RIPK1/MAP4K4/ALK.

　　

 

　　The authors found that LP‑10d can directly bind to RIPK1, MAP4K4, and ALK, exhibiting favorable selectivity, safety, and pharmacokinetic (PK) properties, and effectively inhibits necroptosis in microglia.

　　| LP10d rescues early cognitive deficits in an AD transgenic mouse model.

　　

 

　　In the APP/PS1 and 3xTg mouse models, LP-10d significantly improved spatial learning and memory, with efficacy surpassing that of Nec-1s, suggesting that it can ameliorate or reverse early‑stage cognitive deficits in Alzheimer’s disease.

　　| LP-10d exhibits multitarget activity against multiple AD-like pathologies in 3xTg mice

　　

 

　　LP-10d reduces the phosphorylation of RIPK1, MAP4K4, and ALK in the hippocampus of 3xTg mice, ameliorates microglial necroptosis, modulates the levels of Aβ oligomers, p‑Tau181, and β‑III tubulin, exerts anti‑inflammatory effects, and regulates the expression of relevant genes, thereby demonstrating a multitarget pharmacological profile.

　　Summary

　　Currently, multi‑target drug design faces numerous challenges. Fragment‑based drug discovery (FBDD) and phenotypic screening hold promising potential, yet rational approaches for designing drugs targeting more than two distinct targets remain scarce. In this study, leveraging the microglial necroptotic phenotype and the RFD methodology, we designed a multi‑target ligand, LP‑10d, that simultaneously engages RIPK1, MAP4K4, and ALK. This compound demonstrated favorable efficacy in an Alzheimer’s disease mouse model, offering an innovative strategy for multi‑target drug discovery.

　　The 5-month-old double-transgenic APPswe/PSEN1dE9 (APP/PS1) mice and the 8-month-old triple-transgenic PS1M146V/APPswe/tauP301L (3xTg) mice used in the experiments, along with their littermate wild-type (WT) control mice, were all provided by Aniphe BioLab.

　　Jiangsu Aniphe BioLab Inc., established in 2018, is committed to becoming an internationally renowned preclinical pharmacodynamic evaluation company in the new era of biopharmaceutical development. Aniphe BioLab has built a comprehensive SPF‑grade laboratory animal facility that integrates animal breeding and husbandry, disease model development, and animal experimentation, covering areas such as oncology, neuroscience, and metabolism.

　　With over 5,000 mouse and rat cages at its disposal, and backed by a highly skilled technical team and an extensive animal resource base, Aniphe BioLab offers a wide array of disease‑specific animal models, including cerebral ischemia–reperfusion models in mice and rats (MACO/R), myocardial infarction and myocardial ischemia (MI), transverse aortic constriction (TAC), patient‑derived xenograft (PDX) tumor models, cell‑line‑derived xenograft (CDX) tumor models, spinal cord injury (SCI) models, epilepsy models, and Alzheimer’s disease (AD) models. We also provide pharmacological and efficacy evaluation services tailored to these disease models. We warmly welcome inquiries from all interested clients!

PREVIOUS:

Customer Article | Nature Communications (IF = 12.121): Senescent-like macrophages mediate endplate‑induced vascularization in male mice via IL‑10 secretion

NEXT:

Project Article PNAS (IF = 9.1) | Nano‑Immunomodulation of the Aβ‑Activated Feedback Mechanism in Microglia for Alzheimer’s Disease Therapy